(Q37480893)

20 August 2017

Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study (English)

1 reference

adaptive radiation therapy

20 August 2017

0 references

0 references

1 reference

3

Mack Roach

1 reference

20 August 2017

Jeff M Michalski

1

1 reference

20 August 2017

Kyounghwa Bae

2

1 reference

20 August 2017

Arnold M Markoe

4

1 reference

20 August 2017

Howard M Sandler

5

1 reference

20 August 2017

Janice Ryu

6

1 reference

20 August 2017

Matthew B Parliament

7

1 reference

20 August 2017

William Straube

8

1 reference

20 August 2017

Richard K Valicenti

9

1 reference

20 August 2017

James D Cox

10

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

International Journal of Radiation Oncology Biology Physics

20 August 2017

1 reference

20 August 2017

76

1 reference

20 August 2017

1

1 reference

20 August 2017

14-22

1 reference

Is alpha/beta for prostate tumors really low?

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795116

Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795116

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795116

Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795116

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795116

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795116

Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795116

Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795116

Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795116

Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2795116

A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low

2 September 2018

1 reference

12 December 2020

Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate Cancer

1 reference

12 December 2020

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

1 reference

12 December 2020

Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience

1 reference

12 December 2020

Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V

1 reference

12 December 2020

Fractionation and protraction for radiotherapy of prostate carcinoma

1 reference

12 December 2020

Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect

1 reference

12 December 2020

10.1016/J.IJROBP.2009.01.062

Identifiers

DOI

1 reference

release_y5bvj33b4fhpdfvlfouiisxefe

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/y5bvj33b4fhpdfvlfouiisxefe

24 November 2022

mapped directly with Wikidata item

1 reference

20 August 2017

PubMed publication ID

19577865

1 reference